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Abstract
Introduction: Thalassemia could interfere with some assays for haemoglobin A1c (HbA1c) measurement, therefore, it is useful to be able to screen 
for thalassemia while measuring HbA1c. We used Capillarys 2 Flex Piercing (Capillarys 2FP) HbA1c programme to simultaneously measure HbA1c and 
screen for thalassemia.
Materials and methods: Samples from 498 normal controls and 175 thalassemia patients were analysed by Capillarys 2FP HbA1c programme 
(Sebia, France). For method comparison, HbA1c was quantified by Premier Hb9210 (Trinity Biotech, Ireland) in 98 thalassaemia patients samples. For 
verification, HbA1c from eight thalassaemia patients was confirmed by IFCC reference method. 
Results: Among 98 thalassaemia samples, Capillarys 2FP did not provide an HbA1c result in three samples with HbH due to the overlapping of 
HbBart’s with HbA1c fraction; for the remaining 95 thalassaemia samples, Bland-Altman plot showed 0.00 ± 0.35% absolute bias between two 
systems, and a significant positive bias above 7% was observed only in two HbH samples. The HbA1c values obtained by Capillarys 2FP were con-
sistent with the IFCC targets (relative bias below ± 6%) in all of the eight samples tested by both methods. For screening samples with alpha (α-) 
thalassaemia silent/trait or beta (β-) thalassemia trait, the optimal HbA2 cut-off values were ≤ 2.2% and > 2.8%, respectively. 
Conclusions: Our results demonstrated the Capillarys 2FP HbA1c system could report an accurate HbA1c value in thalassemia silent/trait, and HbA2 
value (≤ 2.2% for α-thalassaemia silent/trait and > 2.8% for β-thalassemia trait) and abnormal bands (HbH and/or HbBart’s for HbH disease, HbF 
for β-thalassemia) may provide valuable information for screening.
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Introduction
Haemoglobin A1c (HbA1c), the major form of all gly-
cated haemoglobin species, is produced by the 
non-enzymatic addition of glucose residues to va-
line moieties at the N-terminal end of the haemo-
globin (Hb) β-chain (1). HbA1c concentrations are 
used as an index for long-term glycaemic control, 
and have recently been recommended for the di-
agnosis of diabetes mellitus (2-4). Various methods 
have been developed to measure HbA1c, however, 
their accuracy can be adversely affected by the 
presence of haemoglobinopathies (5,6). In addi-
tion, HbA1c provides an estimate of blood glucose 
concentrations over a normal erythrocyte lifespan, 
and any conditions altering erythrocyte survival 
(e.g., haemolytic anaemia, iron deficiency anaemia 
or haemoglobinopathies) may lead to misinterpre-
tation of the HbA1c result and hence misdiagnosis 
and mistreatment (7).
Thalassemia is the most common monogenetic 
disease caused by defects in the synthesis of one 
or more of the haemoglobin chains (8,9). Alpha (α-) 
thalassemia is caused by reduced or absent syn-
thesis of α globin chains, including four main 
forms: α-thalassemia silent, α-thalassemia trait (mi-
nor), HbH (intermedia) and HbBart’s hydrops feta-
lis syndrome (major). Beta (β-) thalassemia is 
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caused by reduced or absent synthesis of β globin 
chains, including three main forms: β-thalassemia 
trait (minor), β-thalassemia intermedia and 
β-thalassemia major. Several studies have suggest-
ed that HbA1c measurement may be affected by 
thalassemia, which is probably due to different 
methods used, and the genotypes of samples (10-
16). In addition, the imbalance of globin chains in 
thalassemia can lead to haemolysis and impaired 
erythropoiesis. A decrease of erythrocyte lifespan 
has been reported in β-thalassemia (17). Therefore, 
it is useful to be able to screen for thalassemia 
while measuring HbA1c. Detection of thalassaemia 
is especially important for the identification of 
couples at risk of having a child with thalassemia 
major.
Recently, Sebia (Evry Cedex, France) introduced a 
capillary electrophoresis (CE) method for the de-
termination of HbA1c using Capillarys 2 Flex Pierc-
ing (Capillarys 2FP). Our previous study indicated 
that HbA1c concentrations measured by Capillarys 
2FP system in normal samples, without haemoglo-
binopathies, showed high correlation and con-
cordance with those obtained using a boronate af-
finity high-performance liquid chromatography 
(HPLC) system, i.e. Premier Hb9210 (Trinity Biotech 
Plc, Bray, Ireland) (5). Further accuracy verification 
demonstrated a great consistency with Interna-
tional Federation of Clinical Chemistry and Labo-
ratory Medicine (IFCC) reference method (HPLC/
CE) values (5). However, the effect of thalassemia 
on the CE method is unclear. The HbA1c pro-
gramme on Capillarys 2FP could provide a rapid 
and reliable separation of HbA2, and HbA2 results 
are systematically lower compared to those ob-
tained with the haemoglobin programme, with an 
average bias of 0.29% (10). HbA2 plays an impor-
tant role in screening programme for thalassemia: 
its decrease might reveal α-thalassemia while its 
increase might indicate β-thalassemia (18). There-
fore, in this study, we evaluated the effect of 
thalassemia on HbA1c measurement using Capil-
larys 2FP by comparison with the Premier Hb9210 
and IFCC reference methods, and, furthermore, as-




The Research and Ethics committees of our institu-
tion approved this study. All subjects were in-
formed on the study contents and provided writ-
ten consents for participation. Blood samples were 
obtained from the Clinical Laboratory of the Sec-
ond Affiliated Hospital of Guangzhou University of 
Chinese Medicine between June 2014 and August 
2014. These samples included 498 healthy adults 
(normal controls) and 175 patients with thalassem-
ia. The 175 thalassemia patients included 51 with 
α-thalassemia silent, 57 with α-thalassemia trait, 7 
with HbH and 60 with β-thalassemia trait. Whole 
blood samples were collected in EDTA-containing 
tubes (2.0 mL, BD Franklin Lakes NJ, USA), divided 
into small aliquots and stored at - 80°C before 
analysis as previously described (19,20). 
Normal control samples were selected from sub-
jects undergoing routine laboratory check-up ex-
aminations. Complete blood count (CBC) parame-
ters were measured with BC-6800 (Mindray Medi-
cal Electronics Co., Shenzhen, China). Inclusion cri-
teria were as follows: Hb concentrations > 130 g/L 
(in men) or > 115 g/L (in women), mean corpuscu-
lar volume (MCV) > 80 fL, HbF < 5% without Hb 
disorders (Hb phenotype analysis was performed 
by Bio-Rad Variant II system (Bio-Rad, Japan) using 
the beta thalassemia programme). Thalassemia 
samples were collected from routine laboratory 
test samples for thalassemia. Gap-polymerase 
chain reaction (PCR) was used to identify the 
α-thalassemia deletion mutations, and PCR re-
verse-blot hybridization was used to detect 
β-thalassemia point mutations (YANENG Biosci-
ence Co. Ltd., Shenzhen, China) (21,22). 
Method comparison
The HbA1c values of 98 thalassemia patients (29 
α-thalassemia silent, 41 α-thalassemia traits, 7 HbH 
and 21 β-thalassemia traits), were quantified by Cap-
illarys 2FP and Premier Hb9210 systems according 
to the manufacturers’ instructions. The analysers 
were calibrated once prior to any sample analysis. 
Because glycated and non-glycated haemoglobins 
are separated regardless of haemoglobin species, 
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thalassemia is unlikely to interfere with the IFCC ref-
erence method and boronate affinity chromatogra-
phy method (23). The boronate affinity HPLC meth-
od Premier Hb9210 was used as the comparative 
method. For verification, eight thalassemia samples 
were sent to Shanghai Center for Clinical Laborato-
ry and confirmed by the IFCC reference method 
HPLC/CE. 
Thalassemia screening
A total of 498 normal controls and 168 thalassemia 
samples (51 α-thalassemia silent, 57 α-thalassemia 
traits, and 60 β-thalassemia traits) were analysed 
by Capillarys 2FP HbA1c programme. 
Statistical analysis
For method comparison, the differences between 
two methods (Capillarys 2FP vs Premier Hb9210) 
were presented in a Bland-Altman plot. The rela-
tive bias was calculated by the Capillarys 2FP value 
against the comparative method (Premier Hb9210) 
value, and > ±7% was considered clinically signifi-
cant (National Glycohemoglobin Standardization 
Programme (NGSP) criterion) (24). For verification 
testing, the relative bias was calculated by the 
Capillarys 2FP value against the IFCC reference 
method value, and the proficiency testing accept-
ance limit of  ± 6% provided by the College of 
American Pathologists (CAP) was set as the accu-
racy limit (25).
Measurement data of HbA2 were normally distrib-
uted and the independent sample t-test was per-
formed to detect statistical difference between any 
two groups. Receiver operating characteristic curve 
(ROC) was applied to determine the best cut-off for 
screening α- and β-thalassemia. A P value of < 0.05 
was considered statistically significant. Statistical 
analysis was performed using the MedCalc version 
14.8.1 (MedCalc Software, Ostend, Belgium). 
Results
Method comparison 
Among the 98 thalassaemia samples, HbA1c was 
not detected by Capillarys 2FP in three samples 
with HbH (Figure 1). For the remaining 95 thalas-
saemia samples with detectable HbA1c, the Bland-
Altman plot showed that the absolute bias of 
HbA1c was 0.00 ± 0.35% between Capillarys 2FP 
and Premier Hb9210 systems, and 3.4% of values 
were discordant (i.e., differences outside the range 
mean ± 2SD) (Figure 2). A significant positive bias 
above 7% was found only in two HbH samples. 
To validate these results, the samples of eight 
thalassemias including two α-thalassemia silent, 
two α-thalassemia trait, two HbH and two 
β-thalassemia trait, were analysed by IFCC refer-
ence method HPLC/CE for HbA1c. The results 
showed that the HbA1c concentrations obtained 
by Capillarys 2FP were consistent with the results 
Figure 1. Haemoglobin A1c analysis by Capillarys 2 Flex Pierc-
ing. (A) Normal control. (B) HbH samples - HbA1c cannot be 
measured (in parenthesis) due to overlapping with the HbBart’s 
fraction.
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obtained by IFCC HPLC/CE reference method, with 
relative bias below ± 6% (Table 1). 
Thalassemia screening 
The HbA2 concentration in α-thalassaemia silent/
trait (0.9 - 2.6%) was significantly lower than nor-
mal controls (1.7 - 2.8%) (P < 0.001, Figure 3A). ROC 
analysis showed an area under curve (AUC) of 0.81 
(95% confidence interval, 0.78 - 0.84) and the opti-
mal cut-off value was ≤ 2.2% with a sensitivity of 
76.9% and specificity of 73.7% (Figure 3B). 
The HbA2 concentration in β-thalassaemia trait 
(4.0 - 5.6%) was significantly higher than normal 
controls (1.7 - 2.8%) (P < 0.001, Figure 3A). ROC 
analysis demonstrated an AUC of 1.00 (95% confi-
dence interval, 0.99 - 1.00) and the optimal cut-off 
value was > 2.8% with sensitivity 100% and speci-
ficity 100% (Figure 3C). 
Discussion
Our results indicate that the presence of 
α-thalassaemia silent/trait and β-thalassemia trait 
had no significant effect on the accuracy of HbA1c 
measurement by Capillarys 2FP. Previous studies 
have also revealed agreement between Capillarys 
2FP and Trinity Biotech Ultra2 (boronate affinity 
chromatography method) or Adams Arkray HA-
8160 (ion-exchange HPLC method) systems for 
β-thalassemia samples (14,26). However, HbA1c 
concentrations in some HbH samples became im-
measurable as HbH was separated as the first frac-
tion and the HbBart’s fraction overlapped with 
HbA1c. Thus, Capillarys 2FP could provide valuable 
information (HbH and/or HbBart’s) for immeasura-
ble samples. For some measurable HbH samples 




























Figure 2. Bland-Altman plot showing the differences in hae-
moglobin A1c results between Capillarys 2 Flex Piercing (Capil-
larys 2FP) and Premier Hb9210 systems in thalassaemia samples 
(NGSP units, %). Solid line (mean) – mean difference. Dotted 
lines - 95% confidence interval of mean difference. Dashed lines 
(± 1.96 SD) - ± 1.96 standard deviation of mean difference. 
Table 1. HbA1c concentrations obtained by IFCC and Capillarys 2FP
Genotype
IFCC reference method Capillarys 2FP Relative bias
(%)IFCC units, mmol/mol NGSP units, % IFCC units, mmol/mol NGSP units, %
1 -α3.7/aa 39 5.7 41 5.9 3.5
2 -α4.2/aa 40 5.8 42 6.0 3.4
3 --SEA/aa 30 4.9 28 4.7 - 4.1
4 --SEA/aa 29 4.8 29 4.8 0.0
5 -α3.7/--SEA 21 4.1 23 4.3 4.9
6 -α3.7/--SEA 31 5.0 32 5.1 2.0
7 CD41-42 31 5.0 30 4.9 - 2.0
8 CD41-42 38 5.6 40 5.8 3.6
HbA1c - haemoglobin A1c. IFCC - International Federation of Clinical Chemistry and Laboratory Medicine. Capillarys 2FP - Capillarys 
2 Flex Piercing. NGSP - National Glycohemoglobin Standardization Programme. The relative bias was calculated in NGSP units, as 
the Capillarys 2FP value against the IFCC reference method value. The proficiency testing acceptance limit ± 6% of CAP was set as 
the accuracy limit (25).
https://doi.org/10.11613/BM.2017.030704 Biochem Med (Zagreb) 2017;27(3):030704 
  5
Ke P. et al. Measurement of HbA1c and HbA2 by Capillarys 2FP
by Capillarys 2FP, the results were consistent with 
that by IFCC reference method. 
The limitations of our study are the insufficient 
number of HbH samples and IFCC reference meth-
od confirmed samples. Another limitation of our 
study is the lack of β-thalassemia intermedia/ma-
jor samples. The β-thalassemia is characterized by 
variable increases in HbF and unusually high HbA2 
concentrations. Our previous study found that an 
increased proportion of HbF could affect the HbA1c 
results using Capillarys 2FP (5). Thus, the 
β-thalassemia intermedia/major sample with high-
ly elevated HbF (> 10%) could interfere the HbA1c 
measurement by Capillarys 2FP. Capillarys 2FP 
could report an accurate HbA1c value in 
β-thalassaemia trait and provide valuable informa-
tion (elevated HbA2 and/or HbF) for β-thalassemia 
intermedia/major. Further investigation is warrant-
ed using a larger number of thalassemia interme-
dia/major patient samples.
HbA2 is well separated and quantified by the HbA1c 
programme on Capillarys 2FP, while most other 
HbA1c methods are not able to separate HbA2 from 
HbA0. In the present study, we found the optimal 
HbA2 cut-off values for screening samples with 
α-thalassaemia silent/trait or β-thalassemia trait 
were ≤ 2.2% and > 2.8%, respectively, which was 
consistent with the previous report for 
β-thalassemia (10). In addition, abnormal bands 
could also provide valuable information for thalas-
semia screening (HbH and/or HbBart’s for HbH dis-
ease, HbF for β-thalassemia). The HbA2 concentra-
tions obtained with the HbA1c programme needs 
to be corrected to obtain the real HbA2 concentra-
tions, which warrants further investigation. Al-
though the HbA2 concentration cannot be report-
ed, laboratories must be cautious when thalas-
semia is suspected based on screening during 
HbA1c measurement and communicate with clini-
cians to note whether the patient is anaemic. Fur-
ther confirmatory analysis for thalassemia and oth-
er indicators to diagnose diabetes are recom-
mended. 
In summary, our data, although limited, demon-
strated that Capillarys 2FP HbA1c system could re-
port accurate HbA1c results in thalassemia silent/
trait, and HbA2 concentrations (≤ 2.2% for 
α-thalassaemia silent/trait and > 2.8% for 
β-thalassemia trait) and abnormal bands (HbH 
and/or HbBart’s for HbH disease, HbF for 
Figure 3. The values of haemoglobin A2 (HbA2) were analyzed by Capillarys 2 Flex Piercing for normal controls and thalassaemia. (A) 
The box-plots show the frequency of HbA2 in normal control, α-thalassaemia silent/trait and β-thalassaemia trait. The horizontal line 
in each box represents the median values. The upper and lower limits of each box correspond to the 25th and 75th percentile values. 
The highest and lowest horizontal bars represent the minimum and maximum values. 
(B) For screening α-thalassaemia silent/trait, the receiver operating characteristic curve (ROC) shows an area under curve (AUC) of 
0.80 (95% confidence interval, 0.78 - 0.84) and cutoff value ≤ 2.2% (sensitivity 76.9%, specificity 73.7%). 
(C) For screening β-thalassaemia trait, ROC shows AUC of 1.00 (95% confidence interval, 0.99 - 1.00) and cutoff value > 2.8% (sensitiv-
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β-thalassemia) may provide valuable information 
for screening. 
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